Where does Nuvation Bio's cash flow data come from?

Every line is extracted from Nuvation Bio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Nuvation Bio NUVB Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$204.63M+64.0%	-$567.94M-649%	-$75.8M+27.3%	-$104.2M-20.0%
Depreciation and amortization	$1.74M+155%	$683K+208%	$222K+11.6%	$199K+8.2%
Stock-based compensation	$35.89M+11.2%	$32.28M+65.4%	$19.51M+19.8%	$16.29M+75.8%
Amortization of debt issuance costs	$310K—	——	——	——
Change in accounts receivable	——	$12.73M—	——	——
Change in accounts payable	——	-$1.65M—	——	-$1.79M—
Change in accrued liabilities	——	$6.84M—	——	——
Change in other assets	$846K-86.0%	$6.03M+928%	$587K—	——
Change in prepaid expenses	$4.42M—	——	-$2.3M—	——
Net cash from operating activities	-$173.43M-33.0%	-$130.41M-91.8%	-$68M+29.2%	-$96.11M-40.9%
Capital expenditures	$8M—	$0-100%	$69K-81.4%	$370K+31.2%
Net cash from investing activities	——	$122.7M+1,275%	$8.92M—	——
Proceeds from issuance of common stock	$10.11M+127%	$4.46M—	——	$939K—
Payment of debt issuance costs	$11.9M-30.7%	$17.16M—	——	——
Net cash from financing activities	$202.54M—	——	$628K—	——
Effect of exchange rate changes on cash	-$265K-158%	$453K—	——	——
Net increase (decrease) in cash	——	——	——	-$31.32M—
Interest paid	$2.88M+745%	$341K—	$0—	——
Income taxes paid	$197K-47.2%	$373K—	$0—	——
Amortization expense related to capitalized debt issuance costs	$310K—	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	$1.09M—	$0—	——	——
Increase Decrease In Commodity Contract Assets And Liabilities	——	-$3.94M—	——	——
Increase (Decrease) in Interest and Dividends Receivable	-$285K-116%	-$132K-111%	$1.22M—	——
Increase Decrease In Inventories And Other Operating Assets	$11.41M—	$0—	——	——
Increase (Decrease) in Prepaid Expense	$4.42M—	——	-$2.3M—	——
Non Cash Interest On Revenue Interest Financing Agreement	-$10.14M—	——	——	——
Non Cash Lease Expense	——	-$172K-157%	-$67K-124%	$285K+54.9%
Payments To Acquire Machinery And Equipment	$354K—	——	$69K-81.4%	$370K+31.2%
Proceeds From Revenue Interest Financing Agreement	——	——	——	——
Fair Value Adjustment Of Warrants	$812K-13.2%	$936K+288%	-$497K+95.1%	-$10.19M-141%
Leased assets obtained in exchange for operating lease liabilities	——	$620K—	——	$2.17M—
Right Of Use Asset Recognized	$3.87M+524%	$620K—	——	——
Free cash flow	-$181.43M-39.1%	-$130.41M-91.6%	-$68.07M+29.4%	-$96.48M-40.9%
Free cash flow	-$181.43M-39.1%	-$130.41M-91.6%	-$68.07M+29.4%	-$96.48M-40.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Nuvation Bio's cash flow data come from?: Every line is extracted from Nuvation Bio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.